Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte antigen 6 complex locus K (LY6K) is a member of the Ly6/uPAR superfamily and is classified as a cancer-testis antigen. It plays a role in male fertility and is overexpressed in various cancers, promoting tumorigenesis and progression. It is considered a potential target for immunotherapy.
LY6K knockdown/silencing can suppress tumor cell proliferation and induce T-cell activation, stimulating anti-tumor immunity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte Antigen 6 Complex Locus K (LY6K).